These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 3158690)

  • 1. MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.
    Rubin SA; Tabak L
    J Am Coll Cardiol; 1985 Jun; 5(6):1422-7. PubMed ID: 3158690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients.
    Kereiakes D; Chatterjee K; Parmley WW; Atherton B; Curran D; Kereiakes A; Spangenberg R
    J Am Coll Cardiol; 1984 Nov; 4(5):884-9. PubMed ID: 6238076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure.
    Martin JL; Likoff MJ; Janicki JS; Laskey WK; Hirshfeld JW; Weber KT
    J Am Coll Cardiol; 1984 Nov; 4(5):875-83. PubMed ID: 6238075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure.
    Uretsky BF; Generalovich T; Reddy PS; Salerni R; Valdes AM; Spangenberg RB; Lang JF; Okerholm RA
    Am J Cardiol; 1984 Aug; 54(3):357-62. PubMed ID: 6235735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
    Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH
    Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response.
    Uretsky BF; Generalovich T; Verbalis JG; Valdes AM; Reddy PS
    J Am Coll Cardiol; 1985 Jun; 5(6):1414-21. PubMed ID: 3158689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term effects of oral enoximone on hemodynamics, exercise capacity, anaerobic threshold, and arrhythmias in congestive heart failure.
    Klauss V; Zwehl W; Mudra H; Huber R; Schmidt R; Scheininger M; Vogler A; Tschaidse O; Dieterich HA; Theisen K
    Klin Wochenschr; 1991 Jul; 69(10):430-5. PubMed ID: 1719270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure.
    Amin DK; Shah PK; Hulse S; Shellock FG; Swan HJ
    Am Heart J; 1984 Nov; 108(5):1285-92. PubMed ID: 6238513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute inotropic stimulation with dopamine in severe congestive heart failure: beneficial hemodynamic effect at rest but not during maximal exercise.
    Maskin CS; Kugler J; Sonnenblick EH; LeJemtel TH
    Am J Cardiol; 1983 Nov; 52(8):1028-32. PubMed ID: 6637818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of acute and chronic minoxidil administration on rest and exercise hemodynamics and clinical status in patients with severe, chronic heart failure.
    Nathan M; Rubin SA; Siemienczuk D; Swan HJ
    Am J Cardiol; 1982 Nov; 50(5):960-6. PubMed ID: 7137047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic effects of vasodilators and long-term response in heart failure.
    Franciosa JA; Dunkman WB; Leddy CL
    J Am Coll Cardiol; 1984 Jun; 3(6):1521-30. PubMed ID: 6325522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study.
    Gilbert EM; Bristow MR; Mason JW
    Am J Cardiol; 1987 Aug; 60(5):57C-62C. PubMed ID: 2956870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
    Petein M; Levine TB; Cohn JN
    Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmias.
    Miles WM; Heger JJ; Minardo JD; Klein LS; Prystowsky EN; Zipes DP
    Am Heart J; 1989 Jan; 117(1):112-21. PubMed ID: 2521415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure.
    Viquerat CE; Kereiakes D; Morris DL; Daly PA; Wexman M; Frank P; Parmley WW; Chatterjee K
    J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):326-32. PubMed ID: 3155761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and long-term hemodynamic response to low-dose enoximone in refractory heart failure.
    McDonald KM; O'Sullivan JJ; McWilliams EW; Conroy RC; Maurer BJ
    Cardiovasc Drugs Ther; 1989 Dec; 3(6):913-8. PubMed ID: 2535057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
    Uretsky BF; Valdes AM; Reddy PS
    Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sulmazole: a new positive inotropic agent].
    Renard M; Jacobs P; Melot C; Dresse A; Bernard R
    Ann Cardiol Angeiol (Paris); 1984; 33(4):219-22. PubMed ID: 6465815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure.
    Kereiakes DJ; Viquerat C; Lanzer P; Botvinick EH; Spangenberg R; Buckingham M; Parmley WW; Chatterjee K
    Am Heart J; 1984 Nov; 108(5):1278-84. PubMed ID: 6238512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.